Burden and challenges in the diagnosis and treatment of histoplasmosis among persons with advanced HIV disease in Uganda, 2025
Clicks: 2
ID: 313498
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #185 of 214 articles by views in Open forum infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 214 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Data on the true burden of histoplasmosis in Uganda are limited, largely due to the scarcity of epidemiological studies. We aimed to describe the nationwide burden of histoplasmosis among persons with advanced HIV disease (AHD), highlighting the major challenges in diagnosis and treatment under routine HIV care. Methods This was a prospective longitudinal study conducted at nine health facilities in Uganda. Persons with AHD (CD4 <200 cells/mm3) were included and followed up for two years. Urine samples were sent to the Central Public Health Laboratories and tested using the Histoplasma galactomannan enzyme immunoassay in batches. Histoplasmosis was defined using standard criteria. Results We enrolled 332 participants with AHD, and 66.6% were newly diagnosed with HIV. Over half were female (51.5%), with a median age of 35 years (Interquartile range - IQR=29-42) for all participants. The median CD4 T-cell count was 73 cells/µL (IQR=30.5-126.5). Eight (2.4%) participants were diagnosed with probable histoplasmosis. None of the cases received the recommended antifungals because they were not available in the country. After two years, five cases were still alive, two were lost to follow-up, and one died. Major challenges included missed diagnosis, low index of clinical suspicion, overlap of symptoms with those of pulmonary TB, high cost, and limited access to antifungals such as voriconazole, itraconazole, radiology and laboratory investigations, and lack of knowledge about treatment guidelines. Conclusions Histoplasmosis occurs at a low frequency among persons with AHD in Uganda. Numerous challenges hinder a definite diagnosis and treatment. However, despite these challenges, survival among persons with AHD in Uganda who have untreated histoplasmosis is relatively good.
| Reference Key |
openalex_W7161168845
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Viola Kasone, Judith Kyokushaba, Patrick Semanda, Proscovia Namuwenge, Henry Oundo, Sauda Namubiru, Grace Najjuka, Grace Nantege, Wilson Nyegenye, Rose Nakityo, Aida Namakula, Susan Nambozo, Bridget Ainembabazi, Joseph Kabanda, Julius Kalamya, Isaac Ssewanyana, Susan Nabadda, David Meya, Richard Kwizera |
| Journal | Open forum infectious diseases |
| Year | 2026 |
| DOI |
10.1093/ofid/ofag302
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.